Detaljerad guide kommer snart
Vi arbetar på en omfattande utbildningsguide för BSA-Based Chemotherapy Dose. Kom tillbaka snart för steg-för-steg-förklaringar, formler, verkliga exempel och experttips.
Body Surface Area (BSA) is a measurement of the total skin surface area of the human body, expressed in square metres (m²). In oncology, BSA is the most widely used metric for individualising chemotherapy dosing, because many cytotoxic drugs exhibit dose-dependent toxicity that correlates better with body surface area than with body weight alone. The rationale for BSA-based dosing dates to the 1950s when researchers observed that metabolic rate — and therefore drug clearance — scales predictably with BSA across mammalian species. BSA-based chemotherapy dosing reduces inter-patient variability in drug exposure by accounting for differences in body size. Multiple formulae have been developed to estimate BSA from height and weight. The Mosteller formula (1987) is the most widely used in clinical practice due to its simplicity: BSA (m²) = square root of (Height in cm × Weight in kg / 3600). The DuBois formula (1916), one of the earliest, is BSA = 0.007184 × Height^0.725 × Weight^0.425, and tends to give slightly lower values at extremes of weight. The Haycock formula is preferred in paediatric oncology. In practical terms, the oncologist calculates the patient's BSA, multiplies it by the prescribed dose in mg/m², and administers the resulting dose. For example, a patient with BSA 1.8 m² receiving carboplatin at 400 mg/m² would receive a total dose of 720 mg. Some drugs (notably carboplatin) use renal-clearance-based dosing (Calvert formula) rather than BSA, but BSA remains the dominant dosing methodology in oncology protocols worldwide.
Mosteller: BSA (m²) = sqrt(Height_cm × Weight_kg / 3600); DuBois: BSA = 0.007184 × Height_cm^0.725 × Weight_kg^0.425; Dose (mg) = BSA (m²) × Prescribed dose (mg/m²)
- 1Measure the patient's height in centimetres and body weight in kilograms. Use actual body weight for most drugs; adjusted or ideal body weight may be used for obese patients per protocol-specific guidance.
- 2Apply the Mosteller formula: multiply height (cm) by weight (kg), divide the product by 3600, then take the square root. This yields BSA in m².
- 3Alternatively, apply the DuBois formula: raise height (cm) to the power of 0.725 and weight (kg) to the power of 0.425, multiply both results together, then multiply by 0.007184.
- 4Round BSA to two decimal places (e.g., 1.76 m²). Most institutions apply BSA caps (typically 2.0–2.2 m²) for morbidly obese patients to limit extreme doses, depending on the protocol.
- 5Obtain the prescribed dose from the chemotherapy protocol (expressed in mg/m² for standard cytotoxics, or mg/m²/day for multi-day regimens).
- 6Multiply the patient's BSA by the prescribed dose per m² to obtain the total dose in mg. Round to an appropriate number based on available vial sizes and local rounding policies.
- 7Verify the calculated dose against protocol-specified maximum doses, prior cycle tolerance, and current performance status before ordering.
Typical adult BSA is 1.6–2.0 m² — this is within normal range
A BSA of 1.82 m² is typical for an average adult. This value would then be multiplied by the prescribed mg/m² to calculate the absolute dose for each chemotherapy drug.
Check against maximum dose limits and prior cycle toxicity before ordering
The BSA-based dose calculation yields 318.5 mg. Local rounding policies may round to the nearest 5 mg or to an available vial size. The prescriber must verify against the protocol maximum.
DuBois gives 1.80 m² vs Mosteller's 1.82 m² — clinically equivalent
Both formulae give similar results for patients of average size. DuBois tends to give slightly lower values in very tall or very heavy patients. Most modern protocols use Mosteller for its simplicity.
Many protocols cap BSA at 2.0–2.2 m² for morbidly obese patients — check protocol
Uncapped BSA of 2.49 m² would yield very high absolute doses. BSA capping policies prevent potentially toxic overdosing, but underdosing in obese patients is associated with inferior treatment outcomes. Protocol-specific guidance should always be followed.
Chemotherapy individualisation: oncology pharmacists calculate absolute chemotherapy doses from BSA for every patient starting or continuing a cytotoxic regimen, ensuring appropriate exposure relative to body size.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Clinical trial design: BSA-based dosing is the standard in phase I–III oncology trials, enabling dose escalation studies and comparison of toxicity and efficacy across patients of varying body sizes.. Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Paediatric oncology: BSA-based dosing is especially critical in children, where the range of body sizes (from a 3-kg neonate to an adolescent approaching adult weight) makes weight- or age-based dosing inadequate.
Multidrug regimen coordination: when multiple chemotherapy drugs are prescribed simultaneously, BSA provides a common denominator for calculating each drug's dose, ensuring consistent treatment intensity across the regimen.. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Electronic prescribing safety: hospital oncology prescribing systems automatically calculate BSA and the resulting absolute dose, with embedded alerts for doses exceeding protocol maximum thresholds.. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Carboplatin — Calvert formula preferred over BSA
{'title': 'Carboplatin — Calvert formula preferred over BSA', 'body': 'Carboplatin dosing uses the Calvert formula: Dose (mg) = Target AUC × (GFR + 25), where GFR is estimated by eGFR or measured by 51Cr-EDTA clearance. This renal clearance-based approach is more accurate for carboplatin than BSA because carboplatin is almost entirely eliminated renally. BSA is not used for carboplatin dosing in standard practice.'}
Paediatric BSA — Haycock formula
{'title': 'Paediatric BSA — Haycock formula', 'body': 'In paediatric oncology, the Haycock formula (BSA = 0.024265 × Height_cm^0.3964 × Weight_kg^0.5378) is preferred over Mosteller or DuBois because it was specifically derived and validated in children. All paediatric chemotherapy protocols should specify which BSA formula to use.'} This edge case frequently arises in professional applications of bsa chemotherapy where boundary conditions or extreme values are involved. Practitioners should document when this situation occurs and consider whether alternative calculation methods or adjustment factors are more appropriate for their specific use case.
Amputees and BSA estimation
Some protocols recommend estimating the contribution of the missing limb to weight and adding it back before BSA calculation to avoid systematic underdosing. Standard limb weight percentages (arm ~5%, thigh ~10%, leg ~7%) are used for adjustment.'}
Ascites and oedema
{'title': 'Ascites and oedema', 'body': 'Significant ascites or peripheral oedema artificially inflates body weight and therefore BSA. Using actual body weight in these patients overestimates BSA and may lead to overdosing. Estimated dry weight or adjusted body weight should be considered in patients with significant fluid overload.'} When encountering this scenario in bsa chemotherapy calculations, users should verify that their input values fall within the expected range for the formula to produce meaningful results. Out-of-range inputs can lead to mathematically valid but practically meaningless outputs that do not reflect real-world conditions.
| Population | Average BSA (m²) | Typical Range (m²) |
|---|---|---|
| Newborn | 0.25 | 0.20–0.30 |
| 1-year child | 0.47 | 0.40–0.55 |
| 5-year child | 0.72 | 0.60–0.85 |
| 10-year child | 1.14 | 1.00–1.30 |
| Adult female | 1.60 | 1.45–1.80 |
| Adult male | 1.90 | 1.70–2.10 |
Why is BSA used for chemotherapy dosing rather than body weight?
BSA correlates better with renal and hepatic clearance of many cytotoxic drugs than weight alone, reducing inter-patient variability in drug exposure. The rationale originates from early pharmacokinetic observations that metabolic rate scales with BSA across species. BSA also accounts for the combined effects of height and weight rather than weight alone.
Which BSA formula is most commonly used in oncology?
The Mosteller formula is the most commonly used in modern clinical oncology due to its mathematical simplicity and accuracy. The DuBois formula, though historically significant, is less commonly used for new calculations. The Haycock formula is preferred in paediatric oncology. This is an important consideration when working with bsa chemotherapy calculations in practical applications. The answer depends on the specific input values and the context in which the calculation is being applied.
Should actual or ideal body weight be used in obese patients?
This varies by drug and protocol. Many oncology centres use actual body weight for chemotherapy BSA calculations with a BSA cap (typically 2.0–2.2 m²) in morbidly obese patients. Some protocols specify adjusted ideal body weight or actual weight without capping. Always refer to the specific chemotherapy protocol guidelines. This is an important consideration when working with bsa chemotherapy calculations in practical applications.
What is a BSA cap and why is it applied?
A BSA cap limits the maximum BSA value used for dose calculations in very large or obese patients, preventing extremely high absolute drug doses that may exceed safe toxicity thresholds. Common caps are 2.0 m² or 2.2 m². However, capping may underdose some patients, so evidence-based protocol guidance should be followed.
Does BSA need to be recalculated each chemotherapy cycle?
Yes. Weight changes during chemotherapy (from nausea, cachexia, or steroid-related weight gain) can change BSA significantly over successive cycles. Most oncology units recalculate BSA at each cycle visit and adjust doses accordingly, particularly if weight has changed by more than 5%. This is an important consideration when working with bsa chemotherapy calculations in practical applications. The answer depends on the specific input values and the context in which the calculation is being applied.
Is BSA-based dosing always used in oncology?
No. Some drugs use fixed flat dosing (e.g., some targeted therapies and immunotherapies), weight-based dosing (mg/kg — used for many antibody-drug conjugates and immunotherapies), or renal function-based dosing (e.g., carboplatin using the Calvert formula based on GFR). BSA dosing is most applicable to classical cytotoxic chemotherapy. This is an important consideration when working with bsa chemotherapy calculations in practical applications.
What is a normal BSA for adults?
Average BSA for adult men is approximately 1.9 m² and for adult women is approximately 1.6 m². Values typically range from 1.5 to 2.2 m² in normal weight adults. Paediatric patients have substantially lower BSA values, ranging from approximately 0.2 m² at birth to adult values in late adolescence. In practice, this concept is central to bsa chemotherapy because it determines the core relationship between the input variables.
What happens if the BSA calculation is incorrect?
An incorrect BSA calculation can lead to chemotherapy overdosing (severe toxicity, treatment-related mortality) or underdosing (inadequate treatment efficacy). Independent double-checking of BSA calculations and chemotherapy doses by two qualified oncology pharmacists or nurses before administration is a mandatory patient safety standard. This is an important consideration when working with bsa chemotherapy calculations in practical applications. The answer depends on the specific input values and the context in which the calculation is being applied.
Proffstips
Always document which BSA formula was used (Mosteller, DuBois, or Haycock), the actual height and weight measured on the day, whether any BSA cap was applied, and whether actual, ideal, or adjusted body weight was used. This documentation is essential for safety, audit, and medicolegal purposes.
Visste du?
The idea that BSA could be estimated from height and weight was first published by DuBois and DuBois in 1916 using measurements from only 9 subjects — including DuBois himself. Despite this remarkably small sample size, the DuBois formula remained the most widely used BSA calculation for over 70 years until simpler alternatives like Mosteller were developed.
Referenser
- ›Mosteller RD. Simplified calculation of body-surface area. NEJM 1987.
- ›DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine 1916.
- ›ASCO Guidelines — Chemotherapy Dosing in Obese Patients. J Clin Oncol 2012.
- ›Calvert AH et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989.
- ›MDCalc — Body Surface Area Calculator (Mosteller, DuBois)